23-Jan-2026
No press releases found.
Seeking Alpha News (Fri, 23-Jan 1:50 PM ET)
Healthcare debate should focus on out-of-pocket costs, not list prices – Novartis CEO
Seeking Alpha News (Thu, 22-Jan 1:04 PM ET)
Market Chameleon (Thu, 20-Nov 6:51 AM ET)
XBI Bullish Call Spread is Undervalued at $4.25
Market Chameleon (Tue, 9-Apr 7:04 AM ET)
The SPDR S&P Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index (the Index ). The S&P Biotechnology Select Industry represents the biotechnology segment of the S&P Total Market Index ( S&P TMI ). The S&P TMI is designed to track the broad U.S. equity market. The biotechnology segment of the S&P TMI comprises the Biotechnology sub-industry. The Index is modified equal weighted.
State Street SPDR S&P Biotech ETF trades on the ARCA stock market under the symbol XBI.
As of January 23, 2026, XBI stock price declined to $128.04 with 10,948,623 million shares trading.
XBI has a beta of 0.90, meaning it tends to be less sensitive to market movements. XBI has a correlation of 0.39 to the broad based SPY ETF.
XBI has a market cap of $8.58 billion. This is considered a Mid Cap stock.
In the last 3 years, XBI traded as high as $132.09 and as low as $63.80.
XBI has outperformed the market in the last year with a price return of +38.2% while the SPY ETF gained +14.2%. XBI has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +19.4% and +2.8%, respectively, while the SPY returned +2.9% and -0.7%, respectively.
XBI support price is $129.33 and resistance is $133.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XBI shares will trade within this expected range on the day.